О журнале |  Редакционная коллегия |  Архив | Текущий номер |  Подписка |  Авторам     


Журнал "Клиническая геронтология"

Роль эндотелина-1 в патогенезе артериальной гипертонии и её осложнений (Cрочно в номер)
Х.И. Ибрагимова, С.Н. Маммаев
ФГБОУ ВО Дагестанский государственный медицинский университет»МЗ РФ, Махачкала, Россия

Факторы риска развития сердечно-сосудистых заболеваний (ССЗ) индуцируют нарушение функции эндотелия (ФЭ), что  является начальным этапом патологических изменений. Одну из основных ролей играет нарушение баланса между прессорными и депрессорными механизмами, определяющими сосудистый тонус. Эндотелин-1 (ЭТ-1) – самый сильный вазоконстриктор человеческого организма. В статье рассматривается роль ЭТ-1 в патогенезе артериальной гипертонии, а также возможные принципы лечения, основанные на восстановлении нарушенного метаболизма эндотелина-1 в организме.
Ключевые слова: эндотелин-1, артериальная гипертония, дисфункция эндотелия
Авторы  заявляют об отсутствии возможных конфликтов интересов.

Role of endothelin-1 in the pathogenesis of hypertension and its complications ((Urgent issue)
Kh.I.  Ibragimova,  S.N. Mammaev
Dagestan State Medical University, Department of Hospital Therapy №1, Dagestan, Makhachkala, Russia
Risk factors for cardiovascular disease induce endothelial dysfunction. This is the initial stage of pathological changes. One of the main roles belongs to imbalance between the pressor and depressor mechanisms. Endothelin-1 - the most powerful vasoconstrictor of human body. The article discusses the role of endothelin-1 in the pathogenesis of hypertension, as well as possible treatment guidelines based on the restoration of disturbed metabolism of endothelin-1 in the body.
Key words: endothelin-1, arterial hypertension, endothelial dysfunction
Authors declare lack of possible conflicts of interests

Литература

  1. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertеns. 2013; 31: 281–357.
  2. Глезер М.Г. Пульсовое АД: почему это важно? М.: Медиком, 2013.
  3. Brunner H., Cockcroft J.R., Deanfield J., Donald A, Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension.  Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 2005 Feb; 23(2):233-46.
  4. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S . Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32 (Suppl 2): S314–321.
  5. Rossi R., Cioni E., Nuzzo A., Origliani G., Modena M.G. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care. 2005 Mar; 28(3):702-707.
  6. Yanagisawa M.A, Kurihara H.,  Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cell. Nature. 1988; 332: 411-415.
  7. Stewart D.J., Levy R.D., Cernacek P., and Langleben D. (1991). Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Annals of internal medicine.  114, 464-469.
  8. Kloog Y., Ambar I., Sokolovsky M., Kochva E., Wollberg Z., Bdolah A.   Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science. 1988 Oct 14; 242(4876):268-270.
  9. Agapitov A.V., Haynes W.G. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2002 Mar;3(1):1-15.
  10. Houde M., Desbiens L., D'Orl?ans-Juste P.. Endothelin-1: Biosynthesis, Signaling and Vasoreactivity. Adv Pharmacol. 2016;77:143-75.
  11. Jackman H.L., Morris P.W., Rabito S.F., Johansson G.B., Skidgel R.A., Erdos E.G. Inactivation of endothelin-1 by an enzyme of the vascular endothelial cells. Hypertension. 1993; 21:925–928.
  12. Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., et.al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994 Aug 12; 78(3):473-485.
  13. Davenport A.P., Hyndman K.A., Dhaun N., Southan C., Kohan D.E., Pollock J.S., Pollock D.M., Webb D.J. Maguire Endothelin. Pharmacol Rev. 2016 Apr; 68(2): 357–418.
  14. Baretella O., Vanhoutte P.M. Endothelium-Dependent Contractions: Prostacyclin and Endothelin-1, Partners in Crime? Adv Pharmacol. 2016; 77:177-208.
  15. Khare A., Shetty S., Ghosh K. Evaluation of markers of endothelial damage in case of young myocardial infarction . Atherosclerosis. 2005; 18: 375-380.
  16. Mc.Murdo L., C. Thiermermann J.R. Vane The endothelin ETB receptor agonist, IRL 1620, causes vasodilation and inhibits ex vivo platelet aggregation in the anaesthetised rabbit. Eur. J. Pharmacol. 1994; 259: 51–55.
  17. Vignon-Zellweger N., Heiden S., Miyauchi T., Emoto N. Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci. 2012 Oct 15;91(13-14):490-500.
  18. Ludka O., Spinar J., Pozd?sek Z., Musil V., Spinarov? L., V?tovec J., Tomandl J. Is there circadian variation of big endothelin and NT-proBNP in patients with severe congestive heart failure? Vnitr Lek. 2010 Jun;56(6):488-493.
  19. Martin P., Ninio D., Krum H. Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertension. Hypertension. 2002; 39 : 821 –824.
  20. Cardillo C., Kilcoyne C.M., Waclawiw M., Cannon R.O. Panza J.A. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999; 33 : 753 –758,
  21. Ahn D., Ge Y., Stricklett P.K., Gill P., Taylor D., Hughes A.K., Yanagisawa M., Miller L., Nelson R.D., Kohan D.E. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J. Clin. Invest. 2004;114 : 504 –511.
  22. Panoulas V.F., Douglas K.M., Smith J.P., Taff? P., Stavropoulos-Kalinoglou A., Toms T.E., Elisaf M.S., Nightingale P. Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium. 2008 Jul-Aug;15(4):203-212.
  23. Vask? A., Spinarov? L., Goldbergov? M., Muzik J. The double heterozygote of two endothelin-1 gene polymorphisms (G8002A and -3A/-4A) is related to big endothelin levels in chronic heart failure. Exp Mol Pathol. 2002 Dec;73(3):230-233.   
  24. Sakai S., Kimura T., Wang Z., Shimojo N., Maruyama H. Endothelin-1-induced cardiomyocyte hypertrophy is partly regulated by transcription factor II-F interacting C-terminal domain phosphatase of RNA polymerase II. Life Sci. 2012 Oct 15;91(13-14):572-577.
  25. Aggarwal PK., Jain V., Srinivasan R., Jha V. Maternal EDN1 G5665T polymorphism influences circulating endothelin-1 levels and plays a role in determination of preeclampsia phenotype. J. Hypertens. 2009 Oct;27(10):2044-2050.
  26. Humbert,M., Sitbon O., and Simonneau G. (2004). Treatment of pulmonary arterial hypertension. The New England journal of medicine 351, 1425-1436.
  27. Gali? N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 2004; 61: 227–237.
  28. Jankowich M.D., Wu W.C., Choudhary G. Association of Elevated Plasma Endothelin-1 Levels With Pulmonary Hypertension, Mortality, and Heart Failure in African American Individuals: The Jackson Heart Study. JAMA Cardiol. 2016 Jul 1;1(4):461-469.
  29. Kumazaki T., Wadhwa R., Kaul S.C., Mitsui Y. Expression of endothelin, fibronectin, and mortalin as aging and mortality markers.       Exp. Gerontol. 1997 Jan-Apr;32(1-2):95-103.
  30. Chen D.D., Dong Y.G., Yuan H., Chen A.F. Endothelin 1 activation of endothelin A receptor/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension. Hypertension. 2012 May;59(5):1037-1043.
  31. Dhaun N., Goddard J., Webb D.J. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol. 2006 Apr;17(4):943-55. Epub. 2006 Mar 15.
  32. Miyauchi Y., Sakai S., Maeda S., Shimojo N., Watanabe S., Honma S., Kuga K., Aonuma K., Miyauchi T. Increased plasma levels of big-endothelin-2 and big-endothelin-3 in patients with end-stage renal disease. Life Sci. 2012 Oct 15;91(13-14):729-732
  33. Perez A.L., Grodin J.L., Wu Y., Hernandez A.F., Butler J., Metra M., Felker G.M., Voors A.A., McMurray J.J., Armstrong P.W., Starling R.C., O'Connor C.M. Tang WH Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. Eur. J. Heart. Fail. 2016 Mar;18(3):290-297.
  34. Boffa G.M., Zaninotto M., Bacchiega E. Nalli Correlations between clinical presentation, brain natriuretic peptide, big endothelin-1, tumor necrosis factor-alpha and cardiac troponins in heart failure patients. Ital. Heart. J. 2005 Feb;6(2):125-132.
  35. Stangl K., Dschietzig T., Richter C., Laule M., Stangl V., Tanis E., Baumann G., Felix S.B. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy.    Circulation. 2000 Sep 5;102(10):1132-1138.
  36. Komai H., Adatia I.T., Elliott M.J., de Leval M.R., Haworth S.G. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg. 1993;106:473–478.
  37. Dhaun N., Goddard J., Webb D.J. The endothelin system and its antagonism in chronic kidney disease. J. Am .Soc Nephrol. 2006 Apr;17(4):943-955. Epub. Ellen E., Gillis, Jennifer M. Sasser, Jennifer C. Sullivan. Endothelin, sex, and pregnancy: unique considerations for blood pressure control in females. Am. J. Physiology - Regulatory, Integrative and Comparative Physiology Published. 2016 15 April;;310:691-R696.
  38. Gibbons G.H. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am. J. Cardiol. 1997 Mar 6;79(5A):3-8.
  39. Gali? N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A., Simonn 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Respir. J. 2015 Oct;46(4):903-975.

Поступила 10. 11. 2016
Принята к опубликованию 26.12.2016

References

  1. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertеns. 2013; 31: 281–357.
  2. Glaser MG Pulse BP: Why is it important? M .: Medic 2013.
  3. Brunner H., Cockcroft J.R., Deanfield J., Donald A, Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension.  Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 2005 Feb; 23(2):233-46.
  4. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S . Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32 (Suppl 2): S314–321.
  5. Rossi R., Cioni E., Nuzzo A., Origliani G., Modena M.G. Endothelial-dependent vasodilation and incidence of type 2 diabetes in a population of healthy postmenopausal women. Diabetes Care. 2005 Mar; 28(3):702-707.
  6. Yanagisawa M.A, Kurihara H.,  Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cell. Nature. 1988; 332: 411-415.
  7. Stewart D.J., Levy R.D., Cernacek P., and Langleben D. (1991). Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Annals of internal medicine.  114, 464-469.
  8. Kloog Y., Ambar I., Sokolovsky M., Kochva E., Wollberg Z., Bdolah A.   Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain. Science. 1988 Oct 14; 242(4876):268-270.
  9. Agapitov A.V., Haynes W.G. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2002 Mar;3(1):1-15.
  10. Houde M., Desbiens L., D'Orl?ans-Juste P.. Endothelin-1: Biosynthesis, Signaling and Vasoreactivity. Adv Pharmacol. 2016;77:143-75.
  11. Jackman H.L., Morris P.W., Rabito S.F., Johansson G.B., Skidgel R.A., Erdos E.G. Inactivation of endothelin-1 by an enzyme of the vascular endothelial cells. Hypertension. 1993; 21:925–928.
  12. Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., et.al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994 Aug 12; 78(3):473-485.
  13. Davenport A.P., Hyndman K.A., Dhaun N., Southan C., Kohan D.E., Pollock J.S., Pollock D.M., Webb D.J. Maguire Endothelin. Pharmacol Rev. 2016 Apr; 68(2): 357–418.
  14. Baretella O., Vanhoutte P.M. Endothelium-Dependent Contractions: Prostacyclin and Endothelin-1, Partners in Crime? Adv Pharmacol. 2016; 77:177-208.
  15. Khare A., Shetty S., Ghosh K. Evaluation of markers of endothelial damage in case of young myocardial infarction . Atherosclerosis. 2005; 18: 375-380.
  16. Mc.Murdo L., C. Thiermermann J.R. Vane The endothelin ETB receptor agonist, IRL 1620, causes vasodilation and inhibits ex vivo platelet aggregation in the anaesthetised rabbit. Eur. J. Pharmacol. 1994; 259: 51–55.
  17. Vignon-Zellweger N., Heiden S., Miyauchi T., Emoto N. Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci. 2012 Oct 15;91(13-14):490-500.
  18. Ludka O., Spinar J., Pozd?sek Z., Musil V., Spinarov? L., V?tovec J., Tomandl J. Is there circadian variation of big endothelin and NT-proBNP in patients with severe congestive heart failure? Vnitr Lek. 2010 Jun;56(6):488-493.
  19. Martin P., Ninio D., Krum H. Effect of endothelin blockade on basal and stimulated forearm blood flow in patients with essential hypertension. Hypertension. 2002; 39 : 821 –824.
  20. Cardillo C., Kilcoyne C.M., Waclawiw M., Cannon R.O. Panza J.A. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension. 1999; 33 : 753 –758,
  21. Ahn D., Ge Y., Stricklett P.K., Gill P., Taylor D., Hughes A.K., Yanagisawa M., Miller L., Nelson R.D., Kohan D.E. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J. Clin. Invest. 2004;114 : 504 –511.
  22. Panoulas V.F., Douglas K.M., Smith J.P., Taff? P., Stavropoulos-Kalinoglou A., Toms T.E., Elisaf M.S., Nightingale P. Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium. 2008 Jul-Aug;15(4):203-212.
  23. Vask? A., Spinarov? L., Goldbergov? M., Muzik J. The double heterozygote of two endothelin-1 gene polymorphisms (G8002A and -3A/-4A) is related to big endothelin levels in chronic heart failure. Exp Mol Pathol. 2002 Dec;73(3):230-233.   
  24. Sakai S., Kimura T., Wang Z., Shimojo N., Maruyama H. Endothelin-1-induced cardiomyocyte hypertrophy is partly regulated by transcription factor II-F interacting C-terminal domain phosphatase of RNA polymerase II. Life Sci. 2012 Oct 15;91(13-14):572-577.
  25. Aggarwal PK., Jain V., Srinivasan R., Jha V. Maternal EDN1 G5665T polymorphism influences circulating endothelin-1 levels and plays a role in determination of preeclampsia phenotype. J. Hypertens. 2009 Oct;27(10):2044-2050.
  26. Humbert,M., Sitbon O., and Simonneau G. (2004). Treatment of pulmonary arterial hypertension. The New England journal of medicine 351, 1425-1436.
  27. Gali? N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 2004; 61: 227–237.
  28. Jankowich M.D., Wu W.C., Choudhary G. Association of Elevated Plasma Endothelin-1 Levels With Pulmonary Hypertension, Mortality, and Heart Failure in African American Individuals: The Jackson Heart Study. JAMA Cardiol. 2016 Jul 1;1(4):461-469.
  29. Kumazaki T., Wadhwa R., Kaul S.C., Mitsui Y. Expression of endothelin, fibronectin, and mortalin as aging and mortality markers.       Exp. Gerontol. 1997 Jan-Apr;32(1-2):95-103.
  30. Chen D.D., Dong Y.G., Yuan H., Chen A.F. Endothelin 1 activation of endothelin A receptor/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension. Hypertension. 2012 May;59(5):1037-1043.
  31. Dhaun N., Goddard J., Webb D.J. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol. 2006 Apr;17(4):943-55. Epub. 2006 Mar 15.
  32. Miyauchi Y., Sakai S., Maeda S., Shimojo N., Watanabe S., Honma S., Kuga K., Aonuma K., Miyauchi T. Increased plasma levels of big-endothelin-2 and big-endothelin-3 in patients with end-stage renal disease. Life Sci. 2012 Oct 15;91(13-14):729-732
  33. Perez A.L., Grodin J.L., Wu Y., Hernandez A.F., Butler J., Metra M., Felker G.M., Voors A.A., McMurray J.J., Armstrong P.W., Starling R.C., O'Connor C.M. Tang WH Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. Eur. J. Heart. Fail. 2016 Mar;18(3):290-297.
  34. Boffa G.M., Zaninotto M., Bacchiega E. Nalli Correlations between clinical presentation, brain natriuretic peptide, big endothelin-1, tumor necrosis factor-alpha and cardiac troponins in heart failure patients. Ital. Heart. J. 2005 Feb;6(2):125-132.
  35. Stangl K., Dschietzig T., Richter C., Laule M., Stangl V., Tanis E., Baumann G., Felix S.B. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy.    Circulation. 2000 Sep 5;102(10):1132-1138.
  36. Komai H., Adatia I.T., Elliott M.J., de Leval M.R., Haworth S.G. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg. 1993;106:473–478.
  37. Dhaun N., Goddard J., Webb D.J. The endothelin system and its antagonism in chronic kidney disease. J. Am .Soc Nephrol. 2006 Apr;17(4):943-955. Epub. Ellen E., Gillis, Jennifer M. Sasser, Jennifer C. Sullivan. Endothelin, sex, and pregnancy: unique considerations for blood pressure control in females. Am. J. Physiology - Regulatory, Integrative and Comparative Physiology Published. 2016 15 April;;310:691-R696.
  38. Gibbons G.H. Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am. J. Cardiol. 1997 Mar 6;79(5A):3-8.
  39. Gali? N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A., Simonn 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Respir. J. 2015 Oct;46(4):903-975.


Programming & design
by I.S.0pаrin